Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy in patients with asthma: RE

This paper describes the design of REACH, an 8-week real-life study that will examine the efficacy of indacaterol acetate/glycopyrronium bromide/mometasone furoate, as compared with a high-dose inhaled corticosteroid/long-acting β2-agonist, in asthmatic patients with refractory cough. The primary endpoint is the change from baseline in Leicester Cough Questionnaire scores after 8 weeks of treatment. The study will also examine change in capsaicin-evoked cough receptor sensitivity and cough frequency using the Vitalograph VitaloJAK cough monitor.